FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/03/082490 [Registered on: 17/03/2025] Trial Registered Prospectively
Last Modified On: 30/12/2024
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Radiation Therapy
Preventive
Dentistry 
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   A Supportive Oral Radiation Protection (SORP) management protocol in patients with head and neck cancer undergoing radiotherapy 
Scientific Title of Study   Clinical effectiveness of a Supportive Oral Radiation Protection (SORP) management protocol in patients with head and neck cancer undergoing radiotherapy: A randomized controlled trial 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Amita Kenkre Kamat 
Designation  Professor and Head 
Affiliation  Goa Dental College and Hospital  
Address  Department of Public Health Dentistry, Goa Dental College and Hospital, Bambolim Goa

North Goa
GOA
403202
India 
Phone  9823199347  
Fax    
Email  amitakam66@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Amita Kenkre Kamat 
Designation  Professor and Head 
Affiliation  Goa Dental College and Hospital  
Address  Department of Public Health Dentistry, Goa Dental College and Hospital, Bambolim Goa

North Goa
GOA
403202
India 
Phone  9823199347  
Fax    
Email  amitakam66@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Atrey J Pai Khot 
Designation  Lecturer 
Affiliation  Goa Dental College and Hospital 
Address  Department of Public Health Dentistry, Goa Dental College and Hospital, Bambolim Goa

North Goa
GOA
403202
India 
Phone  9049735410  
Fax    
Email  atreypaikhot01@gmail.com  
 
Source of Monetary or Material Support  
Department No: 8, Department of Public Health Dentistry, Goa Dental College and Hospital, Bambolim-Goa, India 403202 
 
Primary Sponsor  
Name  Directorate of Health Services 
Address  Non - Communicable Disease Cell, Directorate of Health Services, Campal, Panaji - Goa, India 403001 
Type of Sponsor  Government funding agency 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 2  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Amita Kenkre Kamat  Goa Dental College and Hospital  Department no:8, Department of Public Health Dentistry, Goa Dental College and Hospital, Bambolim-Goa,India 403202
North Goa
GOA 
9823199347

amitakam66@gmail.com 
Dr Shuba Jyothy Bobbili  Goa Medical College and Hospital  OPD No: 17, Department of Radiation Oncology, Goa Medical College and Hospital, Bambolim-Goa, India 403202
North Goa
GOA 
9326238678

shubajyothy@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Goa Dental College and Hospital Institutional Ethics Committee  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: D||Radiation Therapy,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Conventional Care Program   Same dental care except fluoride application during radiation and spacer laced with fluoride gel post radiation  
Intervention  Supportive Oral Radiation Protection (SORP) management protocol   I Pre-Treatment Assessment: -Oral Health Evaluation: Conduct a thorough clinical and radiographic examination to identify and address any pre-existing dental problems. -Patient Education: Inform patients about potential side effects including mucositis, xerostomia, dental decay, and osteoradionecrosis, the importance of oral hygiene, and the need for ongoing dental care during and after treatment. II Precautionary Measures -Adequate hydration with frequent sips of water -Avoid spicy food, sugary foods and beverages -Jaw massage regularly -Restrain from alcohol, smoking, smokeless forms of tobacco -Prescribe prophylactic antibiotics for patients at high risk of infection, especially if they are immunocompromised or exhibit poor oral hygiene. III Emergency and necessary dental treatment: -Grossly decayed teeth. root stumps and tooth proximity to the lesion to be advised for extraction -Teeth with high grade mobility and recession with loss of attachment to be advised for extraction -Removal of plaque, debris and calculus using a mechanical plaque control method (Oral Prophylaxis). -Enamel and dentinal caries to be restored with Glass Ionomer Cement (GIC) -In case of caries involving pulp, Emergency Root Canal Openings (ERCO) can be done, the completion of which will be after the radiotherapy. -Sharp cuspal margin in an around the lesion to be rounded off -Application of Flouride varnish or gel using the standard technique IV Rehabilitation by a Spacer Retainer for home care Spacers will be made up of a translucent type of heat cure polymerizing acrylic resin with thickness of 5-7 mm covering the teeth surfaces up to the cervical third of the teeth (Without Flanges) and providing training to the patient or caregivers towards its use. To be applied for 4 minutes followed by rinsing the mouth thoroughly. V Emphasis on Oral Hygiene Maintenance: -Brushing: Advise the use of a soft-bristled toothbrush and non-abrasive fluoride toothpaste at least twice daily. -Flossing: Encourage gentle flossing daily to prevent plaque buildup. -Mouth Rinse: Recommend a non-alcoholic, antiseptic mouthwash to reduce bacterial load. Saltwater rinses can also be beneficial. 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  80.00 Year(s)
Gender  Both 
Details  -Histopathological diagnosis of HNC
-Primarily receiving definitive radiation with or without chemotherapy or surgery
-Patients included in the study will be adults (≥ 18 years of age)
-Patients willing to participate in the study 
 
ExclusionCriteria 
Details  -Patients with cancers other than HNC
-Patients with secondary or recurrent HNC, distant metastasis, skin cancer, congenital anomaly of the head and neck, and chronic illness.
-Patient with mucositis grade 2 post radiation
-Edentulous patients or having less than 10 teeth
-Patient with restricted mouth opening
-Patient with cognitive impairment, motor disability, non-ambulatory and mentally incapacitated or any previous or current psychiatric illness. 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Sequentially numbered, sealed, opaque envelopes 
Blinding/Masking   Participant and Investigator Blinded 
Primary Outcome  
Outcome  TimePoints 
-To improve oral health status of cancer patients which will be evident clinically with reduced dental caries and gingival scores.
-Early intervention and preventive measures can significantly reduce the risk of severe oral complications.
-Patients can maintain better nutritional intake, experience less pain, and have a more positive treatment experience.
-The oral complications are minimized; patients are more likely to complete their prescribed cancer treatment regimens. 
Baseline, 3 months, 6 months and 1 Year 
 
Secondary Outcome  
Outcome  TimePoints 
-Enhanced Treatment Compliance: The oral complications are minimized; patients are more likely to complete their prescribed cancer treatment regimens.
-The protocol developed in this study will assures uniform practice of oral care across the hospital.
-If the oral protocol intervention is found to be effective, this approach could be incorporated into the clinical setting to promote evidence‑based practice & to maximize patient outcomes. 
Baseline, 3 months, 6 months & 1 Year 
 
Target Sample Size   Total Sample Size="50"
Sample Size from India="50" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 2/ Phase 3 
Date of First Enrollment (India)   27/03/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Introduction

Head and neck cancer (HNC), an umbrella term for malignancies of larynx and hypopharynx, nasal cavity, paranasal sinuses, nasopharynx, oropharynx, oral cavity, and salivary gland, accounts for about half a million cases annually, ranking it as the sixth most common cancer globally.1 Radiotherapy (RT) has a vital role in the treatment for head and neck cancer (HNC) either as a primary and only treatment modality or in conjunction with surgery and/or chemotherapy, sometimes as palliation to ease symptoms of advanced cancer such as pain, bleeding, dysphagia and to treat recurrent lesion.2 A conventional (RT) protocol involves a daily radiation fraction of 2 Gray (Gy) for 5 days per week and is continued for 6-7 weeks. Ionizing radiation causes damage to normal tissues located in the radiation portals.3 Thus, this therapy often complex and frequently associated with significant short-and long-term complications including mucositis, candidiasis, dysgeusia, dysphagia, weight loss, malnutrition, hypo-salivation, increased risk of dental caries, increased risk of progression of periodontal disease, dental hypersensitivity, infections, mucosal atrophy, trismus, neuropathic pain, osteoradionecrosis and a general feeling of malaise.4 Approximately all (90-97%) patients getting irradiation to the head and neck area develop a certain grade of mucositis. Although Radiation caries seems to be inevitable, the rate of caries can be minimized by following a stringent diet regime, regular follow-ups, oral hygiene maintenance along with professional oral prophylaxis at scheduled appointments.5 Osteoradionecrosis (ORN) of the jaw is defined as a non-healing exposure of the bone with necrosis, which starts with a breach in the oral mucosa and persists for at least 3 months in a patient who has undergone previous radiotherapy.6 Radiation produce an electronic backscatter, which may damage the surrounding soft tissue. To prevent post radiation complications, besides conventional care, in the clinical setting, home care shall also be included in the form of a spacer retainer. The polymerising acrylic resin being durable and adjustable shall be used to fabricate the spacers. 7

There is currently no consensus-based protocol for the oral management of patients undergoing radiotherapy with head and neck cancer. It has been shown that oral care alone does not sufficiently lower the incidence of severe oral mucositis in patients with head and neck cancer who are receiving radiotherapy, whereas a systematic and comprehensive oral care protocol may indirectly improve treatment compliance by decreasing the infection risk. Although oral care is essential for radiotherapy-induced oral mucositis, it cannot prevent severe oral mucositis by itself. Non-pharmacological interventions can provide positive effects on improving oral health in patients with HNC undergoing RT. However, no intervention combined with multicomponent oral care strategies has been designed to determine its effect on oral health for patients with HNC.

 

Aim of the study

To provide comprehensive dental treatment for oral cancer patients prior to radiation, during radiation and post radiation to evaluate their outcomes, outline a management strategy for these patients and emphasize the need for obtaining a dental clearance for all HNC patients undergoing RT.

Objectives of the study

-      To assess the oral health related quality of life in patients undergoing radiotherapy for Head and Neck Cancer (HNC)

-   To determine the effect of follow-up SORP management protocol designed to improve oral health in patients with HNC receiving radiotherapy and to develop and establish a protocol for patients with head and neck cancer undergoing radiotherapy.

-    To compare and evaluate the SORP management protocol and Conventional Care Program (CCP) on oral health in patients with head and neck cancer undergoing radiotherapy 

 

Materials and Methods

Study design:

Double arm, parallel-group, Clinical trial

Study setting:

   - Department of Radiation Oncology, Goa Medical College and Hospital

   - Department of Public Health Dentistry, Goa Dental College & Hospital

Study tools:

        - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire              H&N35 (EORTC QLQ-H&N35)

        - World Health Organization Oral Toxicity Scale (WHO Oral Toxicity Scale)

       -The oral hygiene status will be recorded by WHO Dentition status;2013, OHI-S Index (Greene          and Jack R. Vermillion;1960), and gingival index (Loe H. and Silness J. 1963)

Sample size:

                                                                                         X1= 15.08, X2= 19.23

                                                                          SD1= 5.24, SD2= 6.52

                                                                          Î±-error at 5% = 1.96

                                                                          power of test at 80% = 0.842        

                                                                           Effect size: 0.72

Final Sample Size: 25 (each group),

Total sample Size: 50

Sampling Technique

-       A simple random sampling technique. (Table of random numbers)

-  Allocation concealment using SNOSE (sequentially numbered, opaque, sealed envelope) technique


Procedure for measurements including process for standardization

  - QoL will be evaluated using questionnaires prepared by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire H&N35 (EORTC QLQ-H&N35). The results of the QoL questionnaires will be analysed according to the specific scoring manual provided by the EORTC, all scores will be expressed on a scale ranging between 0 to 100.

 - The EORTC QLQ-H&N35 questionnaire consists of 7 multi-item symptom scales (pain, sensory problems, social contact problems, swallowing, social eating problems, speech problems, and reduced sexuality) and 11 single-item symptom scales (nutritional supplement use, mouth opening problems, teeth problems, coughing, painkiller use, weight loss, weight gain, sticky saliva, feeding tube, dry mouth, and feeling ill). Most items were rated on a 4-point scale ranging from 1 (“not at all”) to 4 (“very much”); 5 components used a binary response set (“yes” or “no”). Higher scores in the symptom scale amount to a higher level of symptomatology and a poor QoL.8

-   Procedure for measurements including the process of standardization, standard protocol will be adapted to record indices, and WHO Oral Toxicity Scale.

Statistical Analysis

 Descriptive Statistics will be calculated.

-   Mann-Whitney U test/Unpaired T test will be applied to assess significance difference between 2 group using SPSS v.21, with level of significance p < 0.05.

- McNemar test will be used to assess the changes in scale before and after intervention.

-   Repeated measure ANOVA will be applied to assess the oral hygiene over period of time.

Tangible outcome

 -  The primary outcome will be to improve oral health status of cancer patients which will be evident clinically with reduced dental caries and gingival scores.

 -  Prevention of Complications: Early intervention and preventive measures can significantly reduce the risk of severe oral complications.

 -   Improved Quality of Life: By managing oral symptoms, patients can maintain better nutritional intake, experience less pain, and have a more positive treatment experience.

 -   Enhanced Treatment Compliance: The oral complications are minimized; patients are more likely to complete their prescribed cancer treatment regimens.

 
Close